Longevity gets real, regulatory friction for AI, and climate hits health — Daily read, 2026-09-29

Today's news shows that while longevity science pushes hard, policy lags on new tech and ignores climate's direct body blow.

In today's read: 1. Longevity's next wave: beyond pills, into cells · 2. Policy misfires on health tech, slows access · 3. Climate change: a direct hit to the nervous system and the economy · 4. The GLP-1 effect spills into beauty and wellness · 5. Health data privacy gets complicated: cars, research, and bias

1. Longevity's next wave: beyond pills, into cells

Researchers are moving past simple supplements, focusing on cellular reprogramming, gene therapy, and targeting specific aging pathways like Werner helicase or reactivating immune function. This is about deep biology, not just surface-level fixes.

Look for new drugs and treatments that change how cells function, not just what they consume. Biotech firms with gene-editing platforms and precision oncology will command more attention.

Evidence from today:

Old hearts look younger in a new host body — Nature News — New research in Nature Communications found old mouse hearts transplanted into young mice showed signs of 'de-aging.' The hearts regained youthful function by reducing fibrosis and inflammation, suggesting the young environment changed the cellular makeup of the older organs.
Arvinas starts human trials for new oral cancer immunotherapy — Longevity.Technology — Arvinas dosed the first patient in its Phase 1/2 trial for ARV-6723, an oral PROTAC designed to degrade HPK1, a protein that stops immune cells from fighting cancer. The study will track safety and early effectiveness in adults with advanced solid tumors.
New drug targets Werner helicase for advanced cancer — Nature Medicine RSS — A Phase 1 trial published in Nature Medicine shows promising results for a Werner helicase inhibitor, dubbed WN132, in treating advanced microsatellite instability (MSI) solid tumors. Led by Dr. N. V. Singh at Memorial Sloan Kettering Cancer Center, the study on 21 patients demonstrates the drug's ability to selectively kill cancer cells while sparing healthy ones by targeting DNA repair pathways specific to these tumors.
Prime editing gets big, could fix more genetic issues — Nature Medicine RSS — Prime editing, a precision gene-editing tool, has evolved to fix larger DNA segments, opening the door for correcting more complex genetic errors. This advancement moves us closer to fixing a wider range of conditions by precisely rewriting faulty genes. It means scientists can now target bigger chunks of DNA without cutting the strand entirely.

2. Policy misfires on health tech, slows access

Regulators demand more real-world data for AI medical devices while Medicare cuts automatic extra payments for 'breakthrough' tech. This creates friction, increasing the unit economics hurdle for innovative tools and slowing market entry.

Companies with new devices face longer, costlier approval pathways. This favors established players with deep pockets to fund extensive real-world trials, not agile startups.

Evidence from today:

Regulators demand real-world data for AI medical devices — Nature News — Regulatory bodies like the FDA, EMA, and Health Canada are pushing for AI medical devices to be tested in diverse, real-world patient populations, not just controlled clinical trials. This move aims to ensure these devices work effectively and safely across different demographics and use cases, preventing biased outcomes.
Medicare cuts automatic extra pay for new FDA breakthrough devices — STAT Health Tech — Medicare will no longer automatically provide extra payments for medical devices that the FDA designates as 'breakthrough'. This change means manufacturers now need to apply separately for specific reimbursement, which could slow adoption for new health tech. It affects devices from glucose monitors to advanced neurostimulators.

3. Climate change: a direct hit to the nervous system and the economy

Rising global temperatures and pollution directly impair cognitive function and physical capacity, reduce athletic performance, and stress health systems. This affects nervous system regulation and mental health, translating into massive GDP loss.

Watch for more explicit policy linking climate action to public health and economic stability. Businesses should factor climate resilience into workplace planning and supply chains, especially in high-risk regions.

Evidence from today:

Climate change to slash worker capacity, hit global GDP hard — Nature News — A Nature News report details how rising global temperatures are projected to cut labor capacity by up to 20% by 2050 in some regions. This heat stress means reduced physical work, lower cognitive function, and a massive hit to global GDP, particularly in tropical and subtropical zones. We're talking trillions in lost productivity and a direct impact on nervous system regulation.
Air Pollution Slows Marathon Runners, Especially Novices — Deutsches Ärzteblatt — New research in Sports Medicine found that higher nitrogen dioxide (NO2) air pollution directly correlates with slower marathon finish times, particularly for less experienced runners. The analysis of city marathons showed no detectable effect from fine particulate matter (PM) on performance. This means your race time could literally be choked by bad air, even if you don't feel it.
Australia urged to address climate crisis for public health — Croakey Health Media — Fifty-seven organizations are pushing the Australian government to act on climate finance and end fossil fuel expansion, following catastrophic floods. A new report outlines policy pathways to improve Australia's climate policies. The call for action is framed around the direct health impacts of climate change, demanding political will for change.
German Chancellor Calls Climate Change a Threat to Life and Body — Deutsches Ärzteblatt — German Chancellor Friedrich Merz declared climate change a direct threat to human health, emphasizing its physical toll. Speaking at the Council for Sustainable Development, he linked rising global temperatures to direct risks for people's bodies and overall well-being. This marks a clear policy signal from a major global economy on health impacts of climate.

4. The GLP-1 effect spills into beauty and wellness

Oral GLP-1 drugs for diabetes are showing efficacy, driving a consumer expectation that internal biological mechanisms can be directly targeted for external benefits. This fuels investment in products that bridge metabolism and skin/hair health.

Expect more 'inside-out' beauty and wellness products. Companies that can credibly link internal biological mechanisms (like GLP-1, hormones) to visible outcomes will capture market share. Unilever's bet on this convergence is a strong signal.

Evidence from today:

Oral GLP-1 drug Safiglipron shows promise for early type 2 diabetes — Nature Medicine RSS — Researchers just published results in Nature Medicine for an oral GLP-1 receptor agonist, safiglipron, showing it significantly lowered blood sugar in early type 2 diabetes patients. The randomized, double-blind, placebo-controlled trial included 441 participants, confirming safety and effectiveness. This is another step towards more accessible GLP-1 options for metabolic health.
Unilever bets on GLP-1 and AI to blur beauty and wellness — Glossy — Unilever's Wellbeing division sees GLP-1 drugs and AI-powered health data driving a convergence of beauty and wellness. They're banking on consumers seeking products that address internal biology, like metabolism and skin health, which I get. This isn't just about what's on your face; it's what's happening underneath.

5. Health data privacy gets complicated: cars, research, and bias

Connected cars are now collecting biometric data like HRV, sharing it with third parties. Meanwhile, regulators push for diverse real-world data in AI, and advocacy groups campaign to unlock health records for broader research. This sets up a tension between data utility and individual privacy/bias risk.

The fight over data ownership and access is intensifying. Companies relying on personal biometrics need clear consent models. Policy will struggle to balance research acceleration against privacy and equitable AI outcomes.

Evidence from today:

Your connected car is tracking your nervous system signals — Ars Technica - Science & Health — A new study reveals connected cars collect massive amounts of driver data, including biometric and behavioral signals like stress levels and heart rate variability (HRV), and share it with third parties. This data dump goes beyond driving habits, tracking how you actually feel behind the wheel.
MAHA pushing to unlock health data for research — STAT Health Tech — The MAHA Institute, led by Robert F. Kennedy, Jr., is campaigning for health data to be much more accessible. They argue that opening up these records would allow researchers to study everything from vaccines to chronic diseases and autism more effectively. The goal is faster, better insights into population health.
Regulators demand real-world data for AI medical devices — Nature News — Regulatory bodies like the FDA, EMA, and Health Canada are pushing for AI medical devices to be tested in diverse, real-world patient populations, not just controlled clinical trials. This move aims to ensure these devices work effectively and safely across different demographics and use cases, preventing biased outcomes.

Also moved today

Anthropic joins ARPA-H for clinical AI in health care — STAT Health Tech — Anthropic's new partnership with ARPA-H pushes clinical AI into direct patient care, signaling a big government bet on advanced AI in healthcare.
Gender Bias in Lung Cancer Affects Diagnosis, Treatment — El Médico Interactivo — Gender bias in lung cancer diagnosis and treatment means women face different and often worse outcomes, highlighting systemic oversight in medical care.
Extended oligoarticular JIA shows distinct serum signature in kids — Deutsches Ärzteblatt — Identifying a distinct serum biomarker profile for juvenile arthritis could lead to more precise diagnosis and earlier treatment for children.
German medical aid groups fight new tender plans, citing quality risk — Deutsches Ärzteblatt — German medical aid groups are fighting new competitive bidding plans, warning that cutting costs on devices can degrade patient care and access.
FDA approves AbbVie's Juvmo for Parkinson's, targets dopamine receptors — Longevity.Technology — AbbVie's new Parkinson's drug, Juvmo, is the first selective d1/d5 receptor agonist, offering a new treatment pathway for dopamine regulation.
4DMT starts Phase 3 trial for diabetic macular edema treatment — Longevity Technology — 4DMT's Phase 3 trial for diabetic macular edema using gene therapy aims to offer an alternative to existing treatments for blood sugar-related vision issues.
Blood test identifies cancer neoantigens for targeted immunity — El Médico Interactivo — A new liquid biopsy that identifies tumor-specific proteins and immune T-cells could personalize cancer treatment, moving away from generalized approaches.
Alcohol use differs in Denmark and UK, binge drinking common in both — Videnskab.dk (Health) — Alcohol use differs significantly between Denmark and the UK, but binge drinking remains a common social problem leading to shared health challenges.
Perelel Health, women's vitamin brand, hits $100M run rate — Glossy — Perelel Health, a women's vitamin brand, hit a $100M run rate, showing strong consumer demand in the fertility and perimenopause supplement market.

New this week in wellness goods

FDA approves AbbVie's Juvmo for Parkinson's, targets dopamine receptors — US — The FDA just approved AbbVie's Juvmo (tavapadon) for adults with Parkinson's disease. It's a once-daily pill, the first selective d1/d5 receptor agonist, and can be taken with or without levodopa. The approval comes after positive phase 3 data.
Acuvue Launches Acuval Tears for Dry Eye in Spain — Spain — Johnson & Johnson's Acuvue brand just launched Acuval Tears in Spain, a new medical device to relieve dry eye symptoms like irritation and burning. The product uses a combination of hyaluronic acid and trehalose, aiming to stabilize the tear film and protect the ocular surface from environmental stressors.
CareDx uses AI to predict kidney transplant rejection risk — transplant monitoring — Precision medicine company CareDx rolled out its AI-driven diagnostic platform, AlloSure Plus, in July 2025. The tool predicts kidney transplant rejection risk for patients, aiming to cut down on unnecessary biopsies and allow for earlier, personalized treatment. It's about optimizing patient outcomes post-transplant.
Knix spent 18 months engineering seamless cotton underwear — consumer — Knix developed a new line of seamless cotton underwear, "Invisible Cotton," requiring 18 months, 31 prototypes, and 1,700 hours of wear testing. The focus was on engineering fabric that blends comfort with a truly invisible fit. It's a reminder that getting something simple like underwear right takes obsessive detail.
The Cycle launches functional drinks targeting menstrual hormones — Natural food shelves — A new line of functional beverages called The Cycle launched, using organic sea buckthorn to address different phases of women's hormonal cycles. This aims to fill a gap in the natural food market for period-specific support. It's a product designed for daily consumption throughout the cycle.

Signal map

Global: 24 · Europe: 19 · North America: 9 · Oceania: 3 · Nordics: 2 · UK & Ireland: 1

What I'd watch next

Keep an eye on how new AI device regulations unfold, especially for smaller health tech companies. The climate-health link isn't going away; look for specific government mandates or industry shifts in response.

Where this fits at Kokorology

Understanding these deep biological and market shifts is crucial. For navigating your own nervous system, consider our Nervous System Journal, a tool designed to help you track patterns and build resilience, not just react to the headlines.